Application of 2D/3D image fusion technology in endovascular treatment of May-Thurner syndrome and post-thrombotic syndrome

Objective: To examine the potential applications of image fusion technology in the endovascular treatment of May-Thurner syndrome (MTS) and post-thrombotic syndrome (PTS). Methods: The study selected 75 patients diagnosed with MTS or PTS between July 2021 and January 2023. Of the total number of patients, 45 were included in the digital subtraction angiography (DSA) group, while 30 were included in the image fusion group. The clinical data pertaining to these patients was duly collated and subjected to statistical analysis. Results: The mean values of dose-area product (DAP), cumulative air kerma (CAK), and contrast were significantly lower in the image fusion group than in the DSA group. The DAP in the DSA group and image fusion group was 163.28 (121.91-190.02) Gy·cm² and 70.47 (35.40-121.98) Gy·cm², respectively. The CAK in the DSA group and image fusion group was 450.90 (371.00-687.26) mGy and 218.50 (149.75-389.50) mGy, respectively. The contrast dose in the DSA group was 80.00 ± 15.00 ml, whereas the contrast dose in the image fusion group was 60.00 ± 15.00 ml. Conclusion: The application of image fusion has the potential to reduce the amount of radiation exposure and the quantity of contrast agent during endovascular treatment of May-Thurner syndrome and post-thrombotic syndrome.